IDH1 and infantile convulsions and choreoathetosis: A novel mIDH1 inhibitor, HH2301, designed to suppress R-2-HG activity, has demonstrated superior efficacy in IDH-mutant iCCA patients compared to AG-120—an earlier-generation inhibitor—showed only modest benefit in iCCA clinical trials [85].